• SPX
  • $5,948.71
  • 0.53 %
  • $31.60
  • DJI
  • $43,870.35
  • 1.06 %
  • $461.88
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,204.32
  • 0.68 %
  • $55.05
  • IXIC
  • $18,972.42
  • 0.03 %
  • $6.28
Allarity Therapeutics, Inc. (ALLR) Stock Price, News & Analysis

Allarity Therapeutics, Inc. (ALLR) Stock Price, News & Analysis

Currency in USD Disclaimer

$1.26

$0.07

(5.46%)

Day's range
$1.2
Day's range
$1.28
50-day range
$1.15
Day's range
$3.91
  • Country: US
  • ISIN: US0167443029
52 wk range
$1.15
Day's range
$666


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -9.49
  • Piotroski Score 4.00
  • Grade Neutral
  • Symbol (ALLR)
  • Company Allarity Therapeutics, Inc.
  • Price $1.26
  • Changes Percentage (5.46%)
  • Change $0.07
  • Day Low $1.20
  • Day High $1.28
  • Year High $666.00

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/14/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $2,043.41
  • Trailing P/E Ratio 0
  • Forward P/E Ratio 0
  • P/E Growth 0
  • Net Income $-11,901,000

Income Statement

Quarterly

Annual

Latest News of ALLR

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Allarity Therapeutics, Inc. Frequently Asked Questions

  • What is the Allarity Therapeutics, Inc. stock price today?

    Today's price of Allarity Therapeutics, Inc. is $1.26 — it has increased by +5.46% in the past 24 hours. Watch Allarity Therapeutics, Inc. stock price performance more closely on the chart.

  • Does Allarity Therapeutics, Inc. release reports?

    Yes, you can track Allarity Therapeutics, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Allarity Therapeutics, Inc. stock forecast?

    Watch the Allarity Therapeutics, Inc. chart and read a more detailed Allarity Therapeutics, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Allarity Therapeutics, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Allarity Therapeutics, Inc. stock ticker.

  • How to buy Allarity Therapeutics, Inc. stocks?

    Like other stocks, ALLR shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Allarity Therapeutics, Inc.'s EBITDA?

    Allarity Therapeutics, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Allarity Therapeutics, Inc.’s financial statements.

  • What is the Allarity Therapeutics, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Allarity Therapeutics, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Allarity Therapeutics, Inc.'s financials relevant news, and technical analysis. Allarity Therapeutics, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Allarity Therapeutics, Inc. stock currently indicates a “sell” signal. For more insights, review Allarity Therapeutics, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.